Infographic: Research Questions to Be Tackled by Uterus Transplants

Scientists are banking various samples from recipients of donated uteruses to learn all they can about the biology of the organ, and about transplantation more generally.
Source: The Scientist - Category: Science Tags: Infographics Magazine Issue Source Type: news

Related Links:

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Allogeneic hematopoietic cell transplantation (HCT) provides a curative potential for several hematologic malignancies. There has been a considerable increase in the number of partially matched (haploidentical) transplants performed globally 1. Traditionally, haploidentical transplants were associated with substantial bidirectional alloreactivity, which often resulted in graft failure or severe graft versus host disease (GVHD). However, the use of post-transplant cyclophosphamide (PTCy) in the haploidentical platform has resulted in improved GVHD rates and comparable overall outcomes to fully matched-donor transplants; thu...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Chimeric antigen receptor T-cells (CAR-T) are autologous T-cells re-directed towards a tumor-specific antigen and are a successful modality for patients with relapsed/refractory (R/R) hematological malignancies (HM)1-3. The engineered T-cells are transduced with a CAR molecule that consists of an antigen recognition single-chain variable fragment (scFv), a transmembrane domain, and an intracellular signaling domain, CD3 ζ. The intracytoplasmic and transmembrane portions of a second-generation CAR-T contain signaling domains of costimulatory receptors involved in T-cell activation and durability, such as CD3ζ, CD2...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
This study hypothesizes that TC also contributes to tissue remodelling and regeneration of the human thoracic aorta (HTA). The understanding of tissue homeostasis and regenerative potential of the HTA is of high clinical interest as it plays a crucial role in pathogenesis from aortic dilatation to lethal dissection. Therefore, we obtained twenty-five aortic specimens of heart donors during transplantation. The presence of TCs was detected in different layers of aortic tissue and characterized by immunofluorescence and transmission electron microscopy. Further, we cultivated and isolated TCs in highly differentiated form id...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Source Type: research
CONCLUSIONS: Return to work after heart transplantation is variable, with a tendency to be low, and is lower in patients near to retirement age. Protective factors were related to the social, physical and mental environment.PMID:34562415 | DOI:10.1016/j.amjms.2021.06.022
Source: The American Journal of the Medical Sciences - Category: General Medicine Authors: Source Type: research
Prog Brain Res. 2021;265:231-247. doi: 10.1016/bs.pbr.2021.06.006. Epub 2021 Aug 13.ABSTRACTClinical neurorestorative cell therapies for stroke have been explored for over 20 years. Majority cell therapies have shown neurorestorative effects for stroke on non-double-blind studies. In this review, we summarize types of cell transplantation, transplanted routes, therapeutic time windows, dosage, results of exploring trials or clinical studies, results of multicenter, double-blind or observing-blind, randomized, placebo-controlled clinical trials. The clinical application prospects of majority cell therapies for stroke need t...
Source: Brain Research - Category: Neurology Authors: Source Type: research
This article is protected by copyright. All rights reserved.PMID:34561855 | DOI:10.1002/eji.202149318
Source: European Journal of Immunology - Category: Allergy & Immunology Authors: Source Type: research
Curr Opin Organ Transplant. 2021 Sep 24. doi: 10.1097/MOT.0000000000000923. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Transplantation continues to be the only treatment option for end-stage organ failure when other interventions have failed. Although short-term outcomes have improved due to advances in perioperative care, long-term outcomes continue to be adversely affected by chronic rejection. Little is known about the role microbiota play in modulating alloimmune responses and potentially contributing to graft failure. Initial data have identified a correlation between specific changes of the recipient and/or don...
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Source Type: research
Prog Brain Res. 2021;265:231-247. doi: 10.1016/bs.pbr.2021.06.006. Epub 2021 Aug 13.ABSTRACTClinical neurorestorative cell therapies for stroke have been explored for over 20 years. Majority cell therapies have shown neurorestorative effects for stroke on non-double-blind studies. In this review, we summarize types of cell transplantation, transplanted routes, therapeutic time windows, dosage, results of exploring trials or clinical studies, results of multicenter, double-blind or observing-blind, randomized, placebo-controlled clinical trials. The clinical application prospects of majority cell therapies for stroke need t...
Source: Cell Research - Category: Cytology Authors: Source Type: research
Clin Lymphoma Myeloma Leuk. 2021 Aug 20:S2152-2650(21)00361-X. doi: 10.1016/j.clml.2021.08.003. Online ahead of print.ABSTRACTPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) was historically considered to be a very poor-risk subtype of ALL. However, with the introduction of highly potent BCR-ABL tyrosine kinase inhibitors (TKIs), Ph+ ALL can now be considered relatively favorable-risk acute leukemia. Considering the high rates of measurable residual disease negativity and excellent long-term survival that has been achieved with regimens incorporating later-generation TKIs and particularly with ponat...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
More News: Biology | Learning | Science | Transplants | Universities & Medical Training